Neurorehabilitation News

BOSTON — Two studies presented at the American Academy of Neurology meeting showed treatment with Aptiom improved quality of life scores and reduced frequency in patients with focal seizures.

BOSTON — Transcranial direct current stimulation of the dorsolateral prefrontal cortex increased activation of the area and improved self-reported fatigue in patients with MS, Giuseppina Pilloni, PhD, says in this Healio video.

BOSTON — Treatment with LX9211 reduced pain related to postherpetic neuralgia and may be a valuable addition to current options for peripheral neuropathic pain, according to a presenter at the American Academy of Neurology annual meeting.

BOSTON — Worse cognitive processing speed at baseline was predictive of shorter time to disability progression in patients with MS, according to a poster at the American Academy of Neurology annual meeting.

The American Academy of Neurology has elected Carlayne E. Jackson, MD, FAAN, a neurologist, researcher and professor of neurology and otolaryngology at the University of Texas Health Science Center at San Antonio, as its 38th president.

The FDA has approved Qalsody, an antisense oligonucleotide, to treat individuals with ALS associated with a mutation in the superoxide dismutase 1 gene.

The FDA has granted fast track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping, Avidity Biosciences announced in a press release.

BOSTON — For centenarians hospitalized with stroke, outcomes after treatment were affected by presenting stroke severity and ambulatory status at discharge, according to a poster at the American Academy of Neurology annual meeting.

BOSTON — Mental health symptoms in surrogate decision-makers were highest when patients survived in a dependent state after severe acute brain injury, according to a poster at the American Academy of Neurology annual meeting.

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.